MedTrace Logo

Study to Evaluate the Safety and Pharmacokinetics of ALMB-0166 in Patients With Acute Spinal Cord Injury

NCT05524103 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-11-18

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of ALMB-0166 in patients with acute spinal cord injury.

Conditions

  • Acute Spinal Cord Injury

Interventions

DRUG

ALMB-0166

A single dose of ALMB-0166 injection.

Sponsors & Collaborators

  • AlaMab Therapeutics (Shanghai) Inc.

    lead INDUSTRY

Principal Investigators

  • Tian Jiali, Doctor · Peking Union Medical College

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-15
Primary Completion
2025-02-08
Completion
2025-02-08

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05524103 on ClinicalTrials.gov